Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 10/20 | 0.45 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.37 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25356845 | 1.00 | FOLH1 (0.45) | FOLH1C3AR1SMN1; SMN2NOD1CTDSP1 | |
| SCHEMBL93363 | 0.95 | C3AR1 (0.47) | FOLH1C3AR1NOD1CTDSP1 | |
| SCHEMBL30404095 | 0.95 | C3AR1 (0.47) | FOLH1C3AR1NOD1CTDSP1 | |
| SCHEMBL93364 | 0.95 | C3AR1 (0.47) | FOLH1C3AR1NOD1CTDSP1 | |
| SCHEMBL29888878 | 0.86 | FOLH1 (0.43) | FOLH1SMN1; SMN2NOD1SIRT6SIRT1 | |
| SCHEMBL350358 | 0.86 | FOLH1 (0.43) | FOLH1SMN1; SMN2NOD1SIRT6SIRT1 | |
| SCHEMBL8663352 | 0.86 | FOLH1 (0.43) | FOLH1SMN1; SMN2NOD1SIRT6SIRT1 | |
| SCHEMBL19818159 | 0.86 | SIRT6 (0.40) | FOLH1C3AR1SMN1; SMN2SIRT6SIRT1 | |
| SCHEMBL15302107 | 0.85 | FOLH1 (0.47) | FOLH1SMN1; SMN2NOD1 | |
| SCHEMBL16556662 | 0.84 | FOLH1 (0.62) | FOLH1SMN1; SMN2SIRT6SIRT1SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | claimed |
| US-20260098061-A1 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | PEPTIDREAM INC (JP) | 2026-04-09 | — | — | US | disclosed |
| US-20250376529-A1 | METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS | AMGEN INC. (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4615875-A1 | METHODS FOR TREATING OBESITY | AMGEN INC. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12384849-B2 | Bispecific antibodies with cleavable C-terminal charge-paired tags | AMGEN INC. (US) | 2025-08-12 | — | — | US | disclosed |
| WO-2025151781-A1 | METHODS AND SYSTEMS FOR VISCOSITY PREDICTION AND PROTEIN ENGINEERING | AMGEN INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20240261421-A1 | METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING ANTAGONISTIC BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR)/GLP-1 RECEPTOR AGONIST FUSION PROTEINS | AMGEN INC. (US) | 2024-08-08 | — | — | US | disclosed |
| EP-4399225-A1 | ADAPTATION OF PLATFORM HOSTS TO IGF -MEDIA | Amgen Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024102742-A1 | METHODS FOR TREATING OBESITY | AMGEN INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-4351722-A1 | ENGINEERED NRG-1 VARIANTS WITH IMPROVED SELECTIVITY TOWARD ERBB4 BUT NOT AGAINST ERBB3 | Amgen Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-2081602-A2 | TOXIN PEPTIDE THERAPEUTIC AGENTS | Amgen Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20090118181-A1 | Compositions and methods for producing bioactive fusion proteins | AMGEN INC. | 2009-05-07 | — | — | US | disclosed |
| WO-2008088422-A2 | TOXIN PEPTIDE THERAPEUTIC AGENTS | AMGEN INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| EP-1928502-A2 | MODIFIED FC MOLECULES | Amgen, Inc (US) | 2008-06-11 | — | — | EP | disclosed |
| EP-1896080-A2 | TOXIN PEPTIDES WITH EXTENDED BLOOD HALFLIFE | Amgen, Inc (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20080020978-A1 | CGRP peptide antagonists and conjugates | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
| US-20070269369-A1 | Modified Fc molecules | AMGEN INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070071764-A1 | conjugated polymer drug contains toxin protein and polyethylene glycol; treating autoimmune diseases, such as multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, dermatitis, rheumatoid arthritis, psoriasis; asthma, allergy, restinosis, fibrosis, scleroderma, glomerulonephritis | AMGEN INC. | 2007-03-29 | — | — | US | disclosed |
| WO-2007022070-A2 | MODIFIED FC MOLECULES | AMGEN INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006116156-A2 | TOXIN PEPTIDES WITH EXTENDED BLOOD HALFLIFE | AMGEN INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118181-A1 | Compositions and methods for producing bioactive fusion proteins | HGFAC, HDGF, GRB2 | FOLH1 1734/4885C3AR1 2133/4885SMN1; SMN2 2901/4885 |
| US-20070071764-A1 | conjugated polymer drug contains toxin protein and polyethylene glycol; treating autoimmune diseases, such as multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, dermatitis, rheumatoid arthritis, psoriasis; asthma, allergy, restinosis, fibrosis, scleroderma, glomerulonephritis | F11, F13A1, F12 | FOLH1 1479/4885C3AR1 98/4885SMN1; SMN2 1529/4885 |
| US-20070269369-A1 | Modified Fc molecules | FCGR1A, FCGRT, FCGR2A | FOLH1 126/4885C3AR1 23/4885SMN1; SMN2 4219/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | FOLH1 145/4885C3AR1 3113/4885SMN1; SMN2 2485/4885 |
| US-20260098061-A1 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | EPHA2, EPHA1, EPHB1 | FOLH1 418/4885C3AR1 319/4885SMN1; SMN2 2512/4885 |
| US-20080020978-A1 | CGRP peptide antagonists and conjugates | GRPR, CALCRL, CALCA | FOLH1 523/4885C3AR1 94/4885SMN1; SMN2 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.